Technical Analysis for CDTX - Cidara Therapeutics, Inc.

Grade Last Price % Change Price Change
F 0.69 1.26% 0.01
CDTX closed up 1.26 percent on Monday, March 18, 2024, on 1.26 times normal volume. It ran into resistance at its 50 day moving average.
Earnings due: Mar 21
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Calm After Storm Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Gapped Up Strength 0.00%
20 DMA Resistance Bearish 1.26%
50 DMA Resistance Bearish 1.26%
Shooting Star Candlestick Bearish 1.26%
Stochastic Buy Signal Bullish 1.26%

   Recent Intraday Alerts

Alert Time
50 DMA Support about 9 hours ago
Rose Above 50 DMA about 9 hours ago
60 Minute Opening Range Breakdown about 11 hours ago
Possible Inside Day about 11 hours ago
2x Volume Pace about 13 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cidara Therapeutics, Inc. Description

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation of CD101 for the treatment of recurrent vulvovaginal candidiasis, a prevalent mucosal infection. In addition, it develops a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara Therapeutics is developing its first Cloudbreak development candidate, C001, for the treatment of invasive aspergillosis; and evaluating additional opportunities to expand its Cloudbreak immunotherapy platform to other areas of infectious disease. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Disease Immunotherapy Infectious Diseases Vagina Anti Infectives Candidiasis Immunotherapy Technology

Is CDTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.1
52 Week Low 0.593
Average Volume 489,887
200-Day Moving Average 0.87
50-Day Moving Average 0.70
20-Day Moving Average 0.69
10-Day Moving Average 0.68
Average True Range 0.04
RSI (14) 50.50
ADX 15.1
+DI 20.75
-DI 15.29
Chandelier Exit (Long, 3 ATRs) 0.62
Chandelier Exit (Short, 3 ATRs) 0.77
Upper Bollinger Bands 0.74
Lower Bollinger Band 0.65
Percent B (%b) 0.49
BandWidth 11.95
MACD Line -0.01
MACD Signal Line -0.01
MACD Histogram -0.0014
Fundamentals Value
Market Cap 62.72 Million
Num Shares 90.4 Million
EPS -0.39
Price-to-Earnings (P/E) Ratio -1.78
Price-to-Sales 1.12
Price-to-Book 8.19
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.76
Resistance 3 (R3) 0.77 0.75 0.75
Resistance 2 (R2) 0.75 0.73 0.75 0.75
Resistance 1 (R1) 0.72 0.72 0.71 0.72 0.74
Pivot Point 0.70 0.70 0.70 0.70 0.70
Support 1 (S1) 0.68 0.69 0.67 0.67 0.65
Support 2 (S2) 0.66 0.68 0.66 0.64
Support 3 (S3) 0.63 0.66 0.64
Support 4 (S4) 0.63